3 Beaten-Down Growth Stocks to Buy Right Now_老虎社区_美港股上老虎

3 Beaten-Down Growth Stocks to Buy Right Now

Motley Fool2021-08-02

The future still looks bright for these stocks despite pullbacks this year. Key Points These growth stocks have fallen from previous highs in recent months for several reasons. The long-term ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

SpiritA
·2021-08-02
Great
回复
点赞
举报
收起
- cuteypie:
  really?
  2021-08-02
  回复
  举报
manekineko
·2021-08-02
Nice article
回复
2
举报
Pluto891
·2021-08-02
don't buy
回复
点赞
举报
ricebowl
·2021-08-02
Like and comment pls
回复
点赞
举报
BWMoxx
·2021-08-02
Great
回复
1
举报
OldYee
·2021-08-02
Be extra caution n careful. Pls do due diligence check before deciding. Happy investing.
回复
2
举报
收起
- BlueDaisy:
  Yes
  2021-08-02
  回复
  举报
GeoLegends
·2021-08-02
Way to go
回复
点赞
举报
druvaciam
·2021-08-02
Vertex is great value stock[财迷]
回复
点赞
举报
Des123
·2021-08-02
amazing
回复
点赞
举报
TimXT
·2021-08-02
If there is a risk, there is an opportunity
回复
点赞
举报
TimXT
·2021-08-02
Current civid situation will give opportunity for health sector
回复
点赞
举报
7084a9ca
·2021-08-02
Ok
回复
3
举报
boonk
·2021-08-02
Tdoc
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2156864192?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-02 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2156864192","market":"us","top_or_hot":-1,"title":"3 Beaten-Down Growth Stocks to Buy Right Now","media":"Motley Fool","content":"<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PINS","symbol_name":"Pinterest, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","article_id":"2156864192","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","pubTimestamp":1627908600,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The future still looks bright for these stocks despite pullbacks this year.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PINS":"Pinterest, Inc.","TDOC":"Teladoc Health Inc.","VRTX":"福泰制药"},"translate_title":"3只跌跌不休的成长股应立即买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PINS":0.9,"TDOC":0.9,"VRTX":0.9},"content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","kind":"highlight","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":804999959,"gmtCreate":1627914714771,"gmtModify":1633755307210,"author":{"id":"4087738572528350","authorId":"4087738572528350","name":"SpiritA","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087738572528350","idStr":"4087738572528350"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804999959","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5405200,"gmtCreate":1627916987608,"gmtModify":1635161830783,"authorId":3546519093286207,"author":{"id":3546519093286207,"idStr":"3546519093286207","authorId":3546519093286207,"name":"cuteypie","avatar":"https://static.tigerbbs.com/324f57345522368552a82de3cf71ed5f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804999959,"type":1,"supId":0,"prevId":0,"content":"really?","text":"really?","html":"really?"}],"langContent":"EN"},{"id":804077358,"gmtCreate":1627914157674,"gmtModify":1631891473539,"author":{"id":"3557059841248518","authorId":"3557059841248518","name":"manekineko","avatar":"https://static.tigerbbs.com/2621e2547da4dc7e450da498cd2e8341","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3557059841248518","idStr":"3557059841248518"},"htmlText":"Nice article&nbsp;","listText":"Nice article&nbsp;","text":"Nice article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804077358","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804028694,"gmtCreate":1627912997718,"gmtModify":1633755340494,"author":{"id":"3581937910767045","authorId":"3581937910767045","name":"Pluto891","avatar":"https://static.tigerbbs.com/c9963f2ef3d3ad2aff28340461d3d6d0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581937910767045","idStr":"3581937910767045"},"htmlText":"don't buy","listText":"don't buy","text":"don't buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804028694","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804018314,"gmtCreate":1627911854938,"gmtModify":1633755362202,"author":{"id":"3578561901514206","authorId":"3578561901514206","name":"ricebowl","avatar":"https://static.tigerbbs.com/a9ec802718dde5068862a7df929de4ed","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3578561901514206","idStr":"3578561901514206"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804018314","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805777967,"gmtCreate":1627910589359,"gmtModify":1633755387794,"author":{"id":"4088487325195880","authorId":"4088487325195880","name":"BWMoxx","avatar":"https://static.tigerbbs.com/694294fee8427f7a37139676fc8accaa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088487325195880","idStr":"4088487325195880"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805777967","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805774398,"gmtCreate":1627910541714,"gmtModify":1633755388387,"author":{"id":"4087988953652370","authorId":"4087988953652370","name":"OldYee","avatar":"https://static.tigerbbs.com/5c23051d333adc2bd3e4ab06bd2068ce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087988953652370","idStr":"4087988953652370"},"htmlText":"Be extra caution n careful. Pls do due diligence check before deciding. Happy investing.","listText":"Be extra caution n careful. Pls do due diligence check before deciding. Happy investing.","text":"Be extra caution n careful. Pls do due diligence check before deciding. Happy investing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/805774398","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5404852,"gmtCreate":1627915151827,"gmtModify":1635161858024,"authorId":3582677971530678,"author":{"id":3582677971530678,"idStr":"3582677971530678","authorId":3582677971530678,"name":"BlueDaisy","avatar":"https://static.tigerbbs.com/0747094283743978b62fb8b1ee2cf44c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":805774398,"type":1,"supId":0,"prevId":0,"content":"<u>Yes</u>","text":"<u>Yes</u>","html":"<u>Yes</u>"}],"langContent":"EN"},{"id":805779942,"gmtCreate":1627910198186,"gmtModify":1633755393845,"author":{"id":"3584748254057781","authorId":"3584748254057781","name":"GeoLegends","avatar":"https://static.tigerbbs.com/9b58fc6a4f5903eabaf4a377779a7a2f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584748254057781","idStr":"3584748254057781"},"htmlText":"Way to go","listText":"Way to go","text":"Way to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805779942","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805744919,"gmtCreate":1627909995631,"gmtModify":1631883990688,"author":{"id":"4088707402306530","authorId":"4088707402306530","name":"druvaciam","avatar":"https://static.tigerbbs.com/5c3fb456a34258529f2ed7b7f945e0e8","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"4088707402306530","idStr":"4088707402306530"},"htmlText":"Vertex is great value stock[财迷]&nbsp;","listText":"Vertex is great value stock[财迷]&nbsp;","text":"Vertex is great value stock[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805744919","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":805755319,"gmtCreate":1627909319431,"gmtModify":1633755405022,"author":{"id":"4087685411789360","authorId":"4087685411789360","name":"Des123","avatar":"https://static.tigerbbs.com/ba7602b4b7e3538c8a7d687463663003","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4087685411789360","idStr":"4087685411789360"},"htmlText":"amazing","listText":"amazing","text":"amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805755319","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805759967,"gmtCreate":1627908887059,"gmtModify":1633755408906,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"htmlText":"If there is a risk, there is an opportunity&nbsp;","listText":"If there is a risk, there is an opportunity&nbsp;","text":"If there is a risk, there is an opportunity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805759967","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805750398,"gmtCreate":1627908849214,"gmtModify":1633755409724,"author":{"id":"3586676404731572","authorId":"3586676404731572","name":"TimXT","avatar":"https://static.tigerbbs.com/5761f8f2eec972ac144c2286155bc893","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586676404731572","idStr":"3586676404731572"},"htmlText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","listText":"Current civid situation&nbsp; will give opportunity for health sector&nbsp;","text":"Current civid situation will give opportunity for health sector","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805750398","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805750082,"gmtCreate":1627908836246,"gmtModify":1633755409969,"author":{"id":"4089599132652130","authorId":"4089599132652130","name":"7084a9ca","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4089599132652130","idStr":"4089599132652130"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805750082","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":805724597,"gmtCreate":1627908788219,"gmtModify":1633755411136,"author":{"id":"3580955744929134","authorId":"3580955744929134","name":"boonk","avatar":"https://static.tigerbbs.com/6e58310c6a80ddfbcb69e0989cda7858","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3580955744929134","idStr":"3580955744929134"},"htmlText":"Tdoc&nbsp;","listText":"Tdoc&nbsp;","text":"Tdoc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805724597","repostId":2156864192,"repostType":4,"repost":{"id":"2156864192","kind":"highlight","pubTimestamp":1627908600,"share":"https://www.laohu8.com/m/news/2156864192?lang=&edition=full","pubTime":"2021-08-02 20:50","market":"us","language":"en","title":"3 Beaten-Down Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2156864192","media":"Motley Fool","summary":"The future still looks bright for these stocks despite pullbacks this year.","content":"<blockquote>\n <b>The future still looks bright for these stocks despite pullbacks this year.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>These growth stocks have fallen from previous highs in recent months for several reasons.</li>\n <li>The long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.</li>\n</ul>\n<p>Growth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.</p>\n<p>Those downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.</p>\n<p><img src=\"https://static.tigerbbs.com/2f25620d6b3198b886d31c6dd63b3fca\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Pinterest</h3>\n<p><b><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a></b> reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.</p>\n<p>There was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.</p>\n<p>Most importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.</p>\n<p>Pinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.</p>\n<h3>Teladoc Health</h3>\n<p><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b> is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.</p>\n<p>However, the virtual care provider's recent <a href=\"https://laohu8.com/S/QTWO\">Q2</a> results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.</p>\n<p>There are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.</p>\n<p>The virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.</p>\n<h3><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></h3>\n<p><b><a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</b> shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.</p>\n<p><a href=\"https://laohu8.com/S/FBNC\">First</a>, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.</p>\n<p>However, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with <b>CRISPR Therapeutics</b>&nbsp;to treat rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Thanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Beaten-Down Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Beaten-Down Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","TDOC":"Teladoc Health Inc.","PINS":"Pinterest, Inc."},"source_url":"https://www.fool.com/investing/2021/08/02/3-beaten-down-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156864192","content_text":"The future still looks bright for these stocks despite pullbacks this year.\n\nKey Points\n\nThese growth stocks have fallen from previous highs in recent months for several reasons.\nThe long-term prospects for each stock remain strong, presenting an opportunity for investors to buy now at a discount.\n\nGrowth stocks are supposed to...grow. It's right there in the name. The problem is that growth can come in fits and starts. And sometimes, it comes with downturns in share prices.\nThose downturns can provide opportunities for investors who have a long-term perspective. Of course, the stocks that have fallen on hard times must still have strong prospects. The good news is that in many cases, previous high-flying stocks that tumble lower still do have the potential to bounce back. Here are three such beaten-down growth stocks to buy right now.\n\nImage source: Getty Images.\nPinterest\nPinterest, Inc. reported its second-quarter results last week. The social media stock promptly plunged close to 20%. It's now down 34% from the peak set earlier this year.\nInvestors were disappointed that Pinterest's monthly average users (MAUs) in the U.S. fell 5% year over year. Its global MAUs rose, but only by 9%. That's well below what analysts expected.\nThere was plenty of good news, though. Pinterest's second-quarter revenue more than doubled year over year. Average revenue per user (ARPU) soared 89%. The company also posted a solid profit.\nMost importantly, Pinterest's underlying long-term prospects remain strong. The company is coming off an unusual year, to say the least, with the COVID-19 pandemic fueling ginormous growth. One disappointing quarter for user growth isn't a good reason to give up on Pinterest.\nPinterest's platform is still highly popular. The company continues to make solid progress toward increasing the monetization of the platform. Now appears to be a great opportunity to buy the stock at a significant discount.\nTeladoc Health\nTeladoc Health Inc. is down nearly 50% below its highs from earlier in 2021. As is the case with Pinterest, some investors are worried about Teladoc's slowing growth rate.\nHowever, the virtual care provider's recent Q2 results were better than you might think. Teladoc's big net loss was mainly related to acquisition-related expenses. Key metrics including revenue per member per month and utilization continue to improve.\nThere are several potential growth drivers for Teladoc in the near future. The company's major agreement with large health insurer HCSC should boost revenue beginning early next year. Teladoc also has new products such as Primary360 for personalized primary care that should be attractive to customers.\nThe virtual care market is still only in its infancy. Teladoc is the market leader and is solidifying its position by broadening the scope of its products and services. My view is that this stock should be a big winner over the long run.\nVertex Pharmaceuticals\nVertex Pharmaceuticals shares have fallen 16% below the January high for the biotech stock. There are a couple of reasons why Vertex's performance has been underwhelming.\nFirst, the company missed Wall Street's earnings estimate for the fourth quarter of 2020. Second, Vertex's experimental alpha-1 antitrypsin deficiency (AATD) drug VX-864 wasn't effective enough in a phase 2 study to advance into late-stage testing.\nHowever, there are also several reasons to buy Vertex right now. The company's cystic fibrosis (CF) drug Trikafta/Kaftrio should generate solid sales growth outside of the U.S. Vertex also has some promising pipeline candidates, notably including CTX001, the gene-editing therapy it's developing with CRISPR Therapeutics to treat rare blood disorders beta-thalassemia and sickle cell disease.\nThanks to its virtual monopoly in the CF market, Vertex's cash stockpile continues to grow. Look for the company to use its money to make more business development deals that further bolster its pipeline beyond CF.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":99,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}